Genomma Lab Internacional Announces Results for the Fourth Quarter and Full Year 2025

Core Insights - Genomma Lab Internacional reported a challenging year in 2025, with like-for-like sales declining by -4.3% due to a weak summer beverage season and a softer consumption environment in Mexico [1] - The company achieved a year-end EBITDA margin of 23.4%, demonstrating strong business fundamentals despite topline pressure [1] - Genomma Lab anticipates that growth initiatives will gain traction in the second half of 2026, supporting a recovery in operational leverage [1] Financial Performance Summary - Q4 2025 net sales decreased by -13.9% to MXN 4,017 million, while full-year net sales fell by -5.7% to MXN 17,541 million [1] - Gross profit for Q4 2025 was MXN 2,449 million, a decline of -16.7% year-over-year, with a full-year gross profit of MXN 11,022 million, down -7.6% [1] - Net income from continuous operations decreased by -23.1% for the full year 2025, totaling MXN 1,607 million, and declined by -13.0% in Q4 2025 to MXN 319 million [1] Operational Highlights - The company unlocked MXN 1.1 billion in productivity savings to reinvest in growth initiatives, including product innovation and distribution expansion [1] - The cash-conversion cycle remained healthy at 107 days, indicating effective management of working capital [1] - Despite a -2.2% decline in Mexico sell-out during Q4, underlying consumer demand was confirmed to be resilient [1]